Transaction in Own Shares RNS Number : 0920X Vodafone Group Plc

14 February 2025

## **VODAFONE GROUP PLC**

## TRANSACTIONS IN OWN SECURITIES

14 February 2025

Vodafone Group Plc ("**Vodafone**") announces today that it has purchased the following number of its ordinary shares of US\$0.20<sup>20/21</sup> each from Goldman Sachs International ("GSI"). Such purchase was effected pursuant to instructions issued by Vodafone on 04 February 2025, as announced on 04 February 2025 (the "**Programme**"):

Date of purchase:

Number of ordinary shares purchased:

Highest price paid per share (pence):

Lowest price paid per share (pence):

Volume weighted average price paid per share (pence):

67.06

67.43

Vodafone intends to hold the purchased shares in treasury. Following the purchase of these shares, Vodafone holds 2,105,450,250 of its ordinary shares in treasury and has 25,144,019,548 ordinary shares in issue (excluding treasury shares).

As part of the Programme, GSI purchases Vodafone (213800TB53ELEUKM7Q61) ordinary shares and sells such shares to Vodafone. In connection with the above purchases, on 13 February 2025 GSI (as riskless principal) elected to purchase 38,650,504 Vodafone ordinary shares to sell to Vodafone. A schedule of individual trades carried out by Goldman Sachs on 13 February 2025 is set out below.

http://www.rns-pdf.londonstockexchange.com/rns/0920X\_1-2025-2-13.pdf

## Schedule of purchases - aggregate information

Trading venue	Volume weighted average price (pence per share)	Aggregated volume
AQXE	67.41	2,417,000
BATE	67.49	13,154,000
CHIX	67.41	4,098,000
TRQX	67.41	1,704,000
XLON	67.40	17,277,504

This announcement will also be available on Vodafone's website.

For more information, please contact:

Investor Relations:

investors.vodafone.com

ir@vodafone.co.uk

Media Relations:

Vodafone.com/media/contact

GroupMedia@vodafone.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:rns@lseq.com">rns@lseq.com</a> or visit <a href="mailto:www.rns.com">www.rns.com</a>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

**END** 

**POSSFUESDEISELE**